Literature DB >> 16898574

Anemia and cardiovascular disease in diabetic nephropathy.

Samy I McFarlane1, Moro O Salifu, John Makaryus, James R Sowers.   

Abstract

Cardiovascular disease (CVD) is the major cause of morbidity and mortality in people with diabetes and in those with chronic kidney disease (CKD). Diabetes, occurring in epidemic proportions in the United States and worldwide, is also the leading cause of CKD and kidney failure. Identification of modifiable risk factors for CVD in patients with diabetes and CKD is thus of paramount importance. Anemia is increasingly recognized as a potential CVD risk factor in patients with diabetic nephropathy, in whom it is generally more severe and occurs at an earlier stage of CKD. In this review, we discuss the epidemiologic evidence, pathophysiologic mechanisms, and the current research findings, highlighting the role of anemia as a potential modifiable risk factor for CVD in patients with diabetic nephropathy, a particularly vulnerable population for CVD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898574     DOI: 10.1007/s11892-006-0037-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  S I McFarlane; M Banerji; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  The continuing increase of diabetes in the US.

Authors:  A H Mokdad; E S Ford; B A Bowman; D E Nelson; M M Engelgau; F Vinicor; J S Marks
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

Review 3.  Anaemia management in chronic kidney disease patients: an overview of current clinical practice.

Authors:  Fernando Valderrábano
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

4.  Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.

Authors:  T-Christian H Mix; Robert M Brenner; Mark E Cooper; Dick de Zeeuw; Peter Ivanovich; Andrew S Levey; Janet B McGill; John J V McMurray; Patrick S Parfrey; Hans-Henrik Parving; Brian J G Pereira; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Catherine Stehman-Breen; Robert D Toto; Marc A Pfeffer
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

5.  Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients.

Authors:  M A Bajo; R Selgas; M J Castro; C Jiménez; M J Fernández-Reyes; G Del Peso; F De Alvaro; A L Sanchez-Sicilia
Journal:  Perit Dial Int       Date:  1997 Mar-Apr       Impact factor: 1.756

Review 6.  The relationship between hyperinsulinemia, hypertension and progressive renal disease.

Authors:  Fadi A El-Atat; Sameer N Stas; Samy I McFarlane; James R Sowers
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

7.  The polymorphonuclear leukocyte--a new target for erythropoietin.

Authors:  S Sela; R Shurtz-Swirski; R Sharon; J Manaster; J Chezar; G Shkolnik; G Shapiro; S M Shasha; S Merchav; B Kristal
Journal:  Nephron       Date:  2001-07       Impact factor: 2.847

Review 8.  Heart disease in diabetic patients.

Authors:  Mihaela C Blendea; Samy I McFarlane; Esma R Isenovic; Gregory Gick; James R Sowers
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

9.  CREATE: new strategies for early anaemia management in renal insufficiency.

Authors:  Iain C Macdougall
Journal:  Nephrol Dial Transplant       Date:  2003-06       Impact factor: 5.992

Review 10.  Anemia as a risk factor for cardiovascular disease.

Authors:  Arema A Pereira; Mark J Sarnak
Journal:  Kidney Int Suppl       Date:  2003-11       Impact factor: 10.545

View more
  11 in total

1.  Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.

Authors:  Christi Hayes; Anis Alam; Julie Black-Peart; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

2.  Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy.

Authors:  You-qun Huang; Rong Gou; Yong-shu Diao; Qing-hua Yin; Wen-xing Fan; Ya-ping Liang; Yi Chen; Min Wu; Li Zang; Ling Li; Jing Zang; Lu Cheng; Ping Fu; Fang Liu
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 3.  Diabetes, anemia and CKD: Why TREAT?

Authors:  Ajay K Singh
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

4.  Anaemia, haemoglobin level and cause-specific mortality in people with and without diabetes.

Authors:  Andre Pascal Kengne; Sébastien Czernichow; Mark Hamer; G David Batty; Emmanuel Stamatakis
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

5.  Associations between hemoglobin concentrations and the clinical characteristics of patients with type 2 diabetes.

Authors:  Jin Ook Chung; Dong Hyeok Cho; Dong Jin Chung; Min Young Chung
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

6.  Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study.

Authors:  Zhengri Lu; Genshan Ma; Lijuan Chen
Journal:  Mediators Inflamm       Date:  2020-05-11       Impact factor: 4.711

7.  Erythropoietin stimulating agents in the management of anemia of chronic kidney disease.

Authors:  Amir Hayat; Dhiren Haria; Moro O Salifu
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

8.  HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications.

Authors:  Yufeng Li; Mingming Zhao; Dan He; Xuyang Zhao; Wenjing Zhang; Lixin Wei; Edgar Huang; Liang Ji; Meng Zhang; Belinda Willard; Zuodi Fu; Lijuan Wang; Bing Pan; Lemin Zheng; Linong Ji
Journal:  Lipids Health Dis       Date:  2016-04-14       Impact factor: 3.876

Review 9.  Management of anemia in patients with diabetic kidney disease: A consensus statement.

Authors:  Sarita Bajaj; Brij Mohan Makkar; Vinod K Abichandani; Pradeep G Talwalkar; Banshi Saboo; S S Srikanta; Ashok Das; Sruti Chandrasekaran; P Venkata Krishnan; Arun Shah; Georgi Abraham; Pankaj Tikku; Sushil Kumar
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr

10.  Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data.

Authors:  Heleen van Haalen; James Jackson; Bruce Spinowitz; Gary Milligan; Rebecca Moon
Journal:  BMC Nephrol       Date:  2020-03-07       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.